Navigation Links
Inspire Announces Presentations at Two European Scientific,Conferences

DURHAM, N.C.--(BUSINESS WIRE)--Jun 12, 2007 - Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that scientists and collaborators related to Inspire will present information at the XXVI Congress of the European Academy of Allergology and Clinical Immunology (EAACI) being held June 9-13, 2007 in Goteborg, Sweden and at the 30th European Cystic Fibrosis Society (ECFS) Conference being held June 13-16, 2007 in Belek, Turkey.

The EAACI Congress includes two presentations with clinical data on bilastine, a compound in development by FAES Farma, S.A. for the treatment of allergic rhinitis, which is partnered with Inspire in the United States and Canada, and one presentation with scientific data on epinastine, bilastine and other antihistamines for treating allergies. -0-

-- A Phase 3 Study Comparing the Efficacy and Safety of Once Daily

   Bilastine with Cetirizine and Placebo for the Treatment of Seasonal

   Allergic Rhinitis

   Poster and brief oral presentation on Tuesday, June 12, 2007


-- Treatment with Bilastine Improves Symptoms in Patients with

   Seasonal Allergic Rhinitis (Phase 3 Study Comparing the Efficacy

   and Safety of Once Daily Bilastine with Desloratadine and Placebo

   for the Treatment of Seasonal Allergic Rhinitis)

   Poster and brief oral presentation on Tuesday, June 12, 2007


-- Evaluation of Muscarinic Receptor Antagonism by Antihistamines

   Poster and brief oral presentation on Tuesday, June 12, 2007

The ECFS Conference includes two presentations with clinical data on denufosol, a compound in development by Inspire for the treatment of cystic fibrosis. -0-

-- Deposition and Pharmacokinetic Studies with Inhaled P2Y2 Agonists -

   Evidence of High Lung Delivery and Minimal Systemic Exposure

   Poster presentation on Thursday and Friday, June 14-15, 2007 and

   oral presentation on Thursday, June 14, 2007


-- Reactive Airway Disease and
'"/>




Page: 1 2 3

Related medicine technology :

1. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. Inspire Announces Positive Results of Phase 2 Trial of Epinastine Nasal Spray for Seasonal Allergic Rhinitis
3. Inspire Announces Presentations at 2007 Association for Research in Vision and Ophthalmology Annual Meeting
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:1/15/2014)... January 15, 2014 Shire plc (LSE: SHP, NASDAQ: ... of Fair Trading (OFT) approval condition to the announced tender offer ...   As a result of the waiver, the transaction ... complete the tender offer on January 24, 2014 following the currently ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: ... concerning composition of matter, biological targets, mechanism of action, ... This patent application describes a novel ... (VSRNAs) which interfere with the basic homeostatic cellular processes ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
(Date:7/9/2014)... There has been a sharp increase in the number ... MyChart, the online, interactive service that allows patients to ... providers, schedule appointments, and renew prescriptions. , Over a ... MyChart each year increased five-fold, while the number ... according to a study by Dr. David Gerber ...
(Date:7/9/2014)... extinctions around the world have been linked to ... research from the National Institute for Mathematical and ... may also contribute. , In a series ... causes severe hemorrhage of internal organs in frogs, ... frogs if they are exposed to the virus ...
(Date:7/9/2014)... may smell of flatulence and have a reputation for being ... hydrogen sulfide is now being being found to offer potential ... stroke, heart attacks and dementia. A new compound (AP39), designed ... key to future therapies, by targeting delivery of very small ... inside cells. , Scientists in Exeter have already found ...
(Date:7/9/2014)... most important organs in the human body. Its job ... this is its synthesis function and that ... is its detoxification function. Lack of exercise and too ... liver. The resulting diseased cells can lead to inflammations, ... According to the German Liver Foundation, over five million ...
(Date:7/9/2014)... labels handed out by pharmacists may be misread ... according to new research by the University of ... Blind)., The study, published recently in the ... prescription medications dispensed by pharmacies do not consistently ... simply following recommended guidelines for font size, use ...
Breaking Medicine News(10 mins):Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... VANCOUVER, Jan. 30 /PRNewswire-FirstCall/ - QLT Inc. ("QLT") (NASDAQ: ... its modified "Dutch Auction" tender offer (the "Offer"), which expired ... QLT has accepted for purchase and cancellation 20,000,000 of its ... Share, for a total cost of US$50 million. The purchased ...
... (Nasdaq: LCAV ), a leading provider of laser ... announced that it will release fourth quarter and full year ... 10, 2009. A conference call and webcast to discuss ... 2009 at 10:00 a.m. Eastern time.To access the conference call, ...
... CEO of America,s Health Insurance Plans (AHIP), today issued ... to reauthorize and expand the State Children,s Health Insurance ... is an essential component of comprehensive health care reform. ... by voting to help ensure that no child falls ...
... classified by the government as overweight, and with ... even more difficult for people to lose weight, ... MD from Russia ( www.drolga.com ) offers clients ... on CD at www.drolga.com and through ...
... certification allows pharmacies using the Company,s POS product to comply with ... , ... Fountain Valley, CA (PRWEB) January 30, 2009-- ... of Sale software has received SIGIS (Special Interest Group - IIAS ...
... division of HCPro, Inc., announced today the ... website that provides the pharmaceutical and medical ... educate staff and maintain compliance with government ... training products offered by ePharmaceuticals™ into one ...
Cached Medicine News:Health News:QLT announces final results of tender offer 2Health News:Expert Hypnotherapist Dr. Olga Stevko Offers Clients Simple and Powerful Tools for Lasting Weight Loss; Dr. Olga Combines Hypnotherapy and NLP to Transform Clients' Limi 2Health News:Expert Hypnotherapist Dr. Olga Stevko Offers Clients Simple and Powerful Tools for Lasting Weight Loss; Dr. Olga Combines Hypnotherapy and NLP to Transform Clients' Limi 3Health News:CAM Pharmacy Point of Sale Software Receives SIGIS Certification for IIAS Compliance 2Health News:CAM Pharmacy Point of Sale Software Receives SIGIS Certification for IIAS Compliance 3Health News:ePharmaceuticals™ Announces the Launch of epharmcomply.com 2Health News:ePharmaceuticals™ Announces the Launch of epharmcomply.com 3Health News:ePharmaceuticals™ Announces the Launch of epharmcomply.com 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: